Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COAST1 amlitelimab in moderate-to-severe atopic dermatitis
2022-501196-41-00Phase 3Completed
- Sponsor
- Sanofi
- Start
- May 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 15
01
Overview
Phase 3, randomised, double-blind trial of amlitelimab in atopic dermatitis (AD) (3 arms), sponsored by Sanofi. Primary endpoints: vIGA-AD 0/1 with ≥2-point reduction at Week 24 (EU, EU reference countries, Japan), EASI-75 at Week 24 (EU, EU reference countries, Japan) and 1 more. Started May 2024; status: completed.
02
Drugs
amlitelimab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2022-501196-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501196-41-00.